Race to stop cancer before it starts: new treatment aims to prevent myeloma
NCT ID NCT06100237
Summary
This study is testing whether two different drug combinations can delay or prevent the development of multiple myeloma in people who have high-risk early-stage disease. Researchers will enroll 50 adults with smoldering myeloma to receive either teclistamab plus daratumumab or talquetamab plus daratumumab. The main goal is to see if these treatments can eliminate detectable cancer cells and prevent progression to active myeloma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.